UK clinicians are offering early access to GRAIL's Galleri multi-cancer early detection test while awaiting complete results from the NHS-Galleri trial, which missed its primary endpoint of reducing late-stage cancer incidence, according to 360Dx.
The 140,000-participant trial was designed to generate population-level evidence for NHS coverage decisions. The primary endpoint miss narrows the pathway to NHS reimbursement, though GRAIL may still extract value from secondary endpoints or subgroup analyses when full data are released.
The early clinical access creates a dual-track dynamic for GRAIL: a private-pay or cash-access market that can sustain volume in the near term, alongside reimbursement negotiations that now face higher evidentiary hurdles. The company's ability to convert early interest into covered utilization will depend on what the complete trial readout shows about outcomes in specific cancer types or patient subgroups.
The trial outcome also has broader implications for the MCED segment. Competitors developing blood-based multi-cancer screens will face heightened scrutiny from regulators and payers asking whether any MCED test can demonstrate population-level reductions in late-stage diagnoses or mortality. If the full NHS-Galleri data cannot produce a positive signal in secondary analyses, the category's value proposition may shift from proven clinical utility to a screening tool offered primarily on a self-pay basis in government-funded health systems.
GRAIL, now operating independently following its separation from Illumina, recently announced a partnership with Epic to broaden Galleri test ordering through electronic health record integration. The US market, where employer-sponsored and direct-to-consumer channels are more established, may prove more accessible than the UK's centralized, evidence-driven NHS in the absence of definitive trial results.